XML 32 R22.htm IDEA: XBRL DOCUMENT
v3.22.1

Significant Accounting Policies, Revenue Recognition (Details) $ in Thousands | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2022 USD ($) Target | Dec. 31, 2021 USD ($) PerformanceObligation Component | Mar. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2018 USD ($) | Jun. 30, 2018 Agreement | Dec. 31, 2021 USD ($) PerformanceObligation Component
Revenue Recognition [Abstract] |  |  |  |  |  |  |
Revenue | $ 141,919 |  | $ 111,607 |  |  |  |
Biogen [Member] |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |
Number of agreements | Agreement |  |  |  |  |  | 2 |
ION859 [Member] |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |
Revenue | 10,000 |  |  |  |  |  |
Biogen 2013 Strategic Neurology [Member] |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |
Revenue | $ 18,000 |  |  |  |  |  |
Number of targets advanced | Target | 2 |  |  |  |  |  |
New Antisense Medicines for the Treatment of SMA [Member] | ION306 [Member] |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |
Revenue |  | $ 60,000 |  |  |  |  |
Alnylam [Member] |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |
Revenue |  |  |  | $ 41,200 |  |  |
IONIS-FB-L for Complement-Mediated Diseases [Member] |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |
Upfront payment received |  |  |  |  | $ 75,000 |  |
Biogen 2018 Strategic Neurology [Member] |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |
Milestone payment received and added to transaction price |  | $ 7,500 |  |  |  |  |
Eplontersen Collaboration with AstraZeneca [Member] |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  | $ 200,000
Number of material components | Component |  | 4 |  |  |  |  | 4
Number of separate performance obligations | PerformanceObligation |  | 1 |  |  |  |  | 1
Transaction price |  | $ 200,000 |  |  |  |  | $ 200,000
Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca | 55.00% |  |  |  |  |  |

X
- Definition The number of agreements entered into with the collaboration partner. + References No definition available. + Details
Name: | ions_NumberOfAgreementsWithCollaborationPartner
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of material components identified in the collaboration agreement under Accounting Standards Codification (ASC) 808, Collaborative Arrangements. + References No definition available. + Details
Name: | ions_NumberOfMaterialComponents
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of targets advanced under the collaboration agreement. + References No definition available. + Details
Name: | ions_NumberOfTargetsAdvanced
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of costs associated with the ongoing global Phase 3 development program paid by a collaboration partner under the collaboration agreement. + References No definition available. + Details
Name: | ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner
Namespace Prefix: | ions_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of separate performance obligations under the collaboration agreement. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerTransactionPrice
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The additional amount of consideration the Company earned under the collaboration agreement that is added to the transaction price. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerTransactionPriceAdditions
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of upfront payments received during the period under the collaboration agreement. + References No definition available. + Details
Name: | ions_UpfrontPaymentReceived
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_MajorCustomersAxis=ions_BiogenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_Ion859Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_BiogenCollaboration2013StrategicNeurologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_BiogenCollaborationNewAntisenseMedicinesForTreatmentOfSmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_Ion306Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_AlnylamCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_RocheCollaborationIonisFbLForComplementMediatedDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_BiogenCollaboration2018StrategicNeurologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_AstrazenecaCollaborationEplontersenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |